KOD vs. FENC, IPSC, INMB, ELEV, OPT, IPHA, ADVM, GNFT, ABOS, and CMPX
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Fennec Pharmaceuticals (FENC), Century Therapeutics (IPSC), INmune Bio (INMB), Elevation Oncology (ELEV), Opthea (OPT), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), Genfit (GNFT), Acumen Pharmaceuticals (ABOS), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Kodiak Sciences (NASDAQ:KOD) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Kodiak Sciences has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Fennec Pharmaceuticals' return on equity of 0.00% beat Kodiak Sciences' return on equity.
In the previous week, Fennec Pharmaceuticals had 7 more articles in the media than Kodiak Sciences. MarketBeat recorded 9 mentions for Fennec Pharmaceuticals and 2 mentions for Kodiak Sciences. Fennec Pharmaceuticals' average media sentiment score of 0.67 beat Kodiak Sciences' score of 0.63 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Kodiak Sciences presently has a consensus target price of $5.50, indicating a potential upside of 43.23%. Fennec Pharmaceuticals has a consensus target price of $17.33, indicating a potential upside of 136.15%. Given Fennec Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Kodiak Sciences.
Kodiak Sciences has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
Fennec Pharmaceuticals received 173 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 65.41% of users gave Fennec Pharmaceuticals an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Fennec Pharmaceuticals has higher revenue and earnings than Kodiak Sciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 11.3% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Fennec Pharmaceuticals beats Kodiak Sciences on 11 of the 17 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
